Efficacy of Deutetrabenazine to Control Symptoms of Dysphagia Associated with HD
Efficacy of Deutetrabenazine in Huntington's Disease Patients with Dysphagia: a Randomised, Placebo-controlled Pilot Study
Sponsor: Fundacion Huntington Puerto Rico
Terminated
The study was terminated prematurely due to the lack of availability of the study drug.
Listed as NCT04301726, this PHASE1 trial focuses on Huntington Disease and remains terminated or withdrawn. Sponsored by Fundacion Huntington Puerto Rico, it has been updated 7 times since 2022, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Mar 2025 — Present [monthly]
Terminated PHASE1
Status: Unknown → Terminated
-
Sep 2024 — Mar 2025 [monthly]
Unknown PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1
Status: Unknown Status → Unknown
-
Feb 2023 — Jul 2024 [monthly]
Unknown Status PHASE1
Status: Not Yet Recruiting → Unknown Status
-
Jan 2021 — Feb 2023 [monthly]
Not Yet Recruiting PHASE1
▶ Show 2 earlier versions
-
Aug 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE1
-
Apr 2020 — Aug 2020 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Fundacion Huntington Puerto Rico
For direct contact, visit the study record on ClinicalTrials.gov .